scholarly journals The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial

2020 ◽  
Vol 7 (6) ◽  
pp. 3310-3319
Author(s):  
Martin Schulz ◽  
Nina Griese‐Mammen ◽  
Pia M. Schumacher ◽  
Stefan D. Anker ◽  
Friedrich Koehler ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Heart Failure Patients ◽  
Randomized Controlled ◽  
Physician Care ◽  
The Impact

Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep and Well-being: A Randomized Controlled Trial (Preprint)

2021 ◽  
Author(s):  
Kathleen P. O'Hora ◽  
Raquel A. Osorno ◽  
Dena Sadeghi-Bahmani ◽  
Mateo Lopez ◽  
Allison Morehouse ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Early Treatment ◽  
Controlled Trial ◽  
Well Being ◽  
Control Group ◽  
Randomized Controlled ◽  
The Impact ◽  
Insomnia Symptoms

BACKGROUND The COVID-19 Pandemic led to drastic increases in the prevalence and severity of insomnia symptoms. These increases in insomnia complaints have been paralleled by significant decreases in well-being, including increased symptoms of depression, anxiety, and suicidality and decreased quality of life. However, the efficacy and impact of early treatment of insomnia symptoms on future sleep and well-being remains unknown. OBJECTIVE Here, we present the framework and protocol for a novel study that aims to investigate whether a brief telehealth insomnia intervention targeting new insomnia that developed during the pandemic prevents deterioration of well-being, including symptoms of insomnia, depression, anxiety, suicidality, and quality of life. METHODS The protocol details a two-arm randomized controlled trial to investigate the efficacy of a brief, telehealth-delivered, early treatment of insomnia and evaluate its potential to prevent a deterioration of well-being. Participants with clinically significant insomnia symptoms that began during the pandemic are randomized to either a treatment group or a 28-week waitlist control group. Treatment consists of 4 telehealth sessions of Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered over 5 weeks. All participants will complete assessments of insomnia symptom severity, well-being, and daily habits checklist at baseline (week 0), and at weeks 1-6, 12, 28, and 56. RESULTS The trial began enrollment June 3, 2020 and closed enrollment June 17, 2021. As of October 2021, 49 participants have been randomized to either immediate treatment or a 28-week waitlist. 23 participants are still active in the protocol. CONCLUSIONS To our knowledge, this protocol would be represent the first study to test an early sleep intervention for improving insomnia that emerged during the COVID-19 Pandemic. The findings of this study could provide information about the utility of CBT-I for symptoms that emerge in the context of other stressors before they develop a chronic course and deepen understanding of the relationship between sleep and well-being. CLINICALTRIAL NCT04409743

Effect of behavioral management on quality of life in mild heart failure: a randomized controlled trial

2005 ◽  
Vol 58 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Martha Shively ◽  
Mary Kodiath ◽  
Tom L. Smith ◽  
Ann Kelly ◽  
Patricia Bone ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Behavioral Management ◽  
Randomized Controlled ◽  
Mild Heart Failure
Sign in / Sign up

Export Citation Format

Share Document